VN+) was previously subjected to genome sequencing described by Schürch et al. (Infection, Genetics and Evolution 2011; 11:587-597) . The M. tuberculosis strains in this study were selected on basis of their diverse genotyping results, as determined by using spoligotyping and IS6110 restriction fragment length polymorphism (RFLP) typing according to the internationally standardized methods (Kamerbeek et al. J Clin Microbiol. 1997; 35(4):907-14 and van Embden et al. J Clin Microbiol. 1993; 31(2):406-9) . The genotypes of the strains were defined as either Beijing or EAI according to their characteristic spoligotypes, following the well-accepted genotype definitions described by Kremer et al. (J. Clin Microbiol. 2004; 42(9) :4040-9) and Brudey et al. (BMC Microbiol. 2006; 6:6-23 VN 2002 -1607 , VN 1998 -2115 , and VN 1998 -2145 
Anti-TB Drugs
The anti-TB drugs assayed were isoniazid ( 
Minimal Inhibitory Concentration (MIC)
To determine the MIC of the M. tuberculosis genotype strains we used the agar tuberculosis suspension was plated onto solid media containing serial, twofold dilution concentrations of anti-TB drug. After incubation the degree of growth was assessed. The MIC was defined as the lowest concentration of anti-TB drug that resulted in >99% growth inhibition.
MIC determinations were performed in duplicate.
Mutation Frequency (MF)
Determination of the MF of the M. tuberculosis genotype strains was performed using the suspension were plated onto solid media without drugs and onto solid media containing the "critical concentration" of the respective anti-TB drugs. After incubation, the total numbers of colony forming units (cfu) and numbers of resistant mycobacteria were counted and the MF was calculated. MFs were determined in duplicate. In order to assess the stability of the resistant mutants isolated from the anti-TB drug-containing solid media, 10 colonies were randomly picked and plated onto solid media without anti-TB drug. After incubation, these colonies were plated to check for re-growth on solid media containing the "critical concentration" of the same anti-TB drug.
Time-kill Kinetics
For Beijing-1585 and EAI-1627 a time-kill kinetic assay for rifampin was performed.
The concentration-and time-dependent bactericidal activity of the anti-TB drug was determined as described previously (de Steenwinkel et al. J Antimicrob Chemother. 2010; 65(12) :2582-9).
In short, M. tuberculosis cultures at low density or at high density were exposed to rifampin at 2- 
Mutant Prevention Concentration (MPC)
The MPC of the M. tuberculosis genotype strains was determined using the protocol as tuberculosis.
